BACKGROUND AND PURPOSE: To evaluate treatment results of concurrent chemoradiation with daily low dose cisplatin. MATERIALS AND METHODS: 121 patients with advanced stage HNSCC were treated with RT (35 x 2 Gy) and cisplatin (6 mg/m(2) i.v. x20, daily before RT). After 47 patients, the treatment protocol (Standard Group) was changed: Daily i.v. prehydration and accelerated RT were given to the subsequent 74 patients (Hydr-Ac-RT Group). RESULTS: Mean follow-up was 29 months (range 7-62). More chemotherapy could be administered in the Hydr-Ac-RT Group (maximum no. of 20 cisplatin-infusions increased from 59% to 91% of patients, p=0.008), with less renal toxicity (p<0.001) and less hospital admissions (p<0.02). However, mucositis was more pronounced and tubefeeding more frequent in the Hydr-Ac-RT Group. The CR rate of the primary tumor increased from 74% (Standard Group) to 90% (Hydr-Ac-RT Group) (p=0.06), although this did not lead to an improvement in loco-regional control. CONCLUSIONS: Concurrent chemoradiation with daily low dose cisplatin is feasible and effective for selected patients with advanced HNSCC. Although the addition of accelerated RT resulted in more mucositis and tubefeeding, the introduction of prehydration led to better compliance to therapy with more chemotherapy administered and less hospital admissions.
BACKGROUND AND PURPOSE: To evaluate treatment results of concurrent chemoradiation with daily low dose cisplatin. MATERIALS AND METHODS: 121 patients with advanced stage HNSCC were treated with RT (35 x 2 Gy) and cisplatin (6 mg/m(2) i.v. x20, daily before RT). After 47 patients, the treatment protocol (Standard Group) was changed: Daily i.v. prehydration and accelerated RT were given to the subsequent 74 patients (Hydr-Ac-RT Group). RESULTS: Mean follow-up was 29 months (range 7-62). More chemotherapy could be administered in the Hydr-Ac-RT Group (maximum no. of 20 cisplatin-infusions increased from 59% to 91% of patients, p=0.008), with less renal toxicity (p<0.001) and less hospital admissions (p<0.02). However, mucositis was more pronounced and tubefeeding more frequent in the Hydr-Ac-RT Group. The CR rate of the primary tumor increased from 74% (Standard Group) to 90% (Hydr-Ac-RT Group) (p=0.06), although this did not lead to an improvement in loco-regional control. CONCLUSIONS: Concurrent chemoradiation with daily low dose cisplatin is feasible and effective for selected patients with advanced HNSCC. Although the addition of accelerated RT resulted in more mucositis and tubefeeding, the introduction of prehydration led to better compliance to therapy with more chemotherapy administered and less hospital admissions.
Authors: Jantien Hoek; Karen M Bloemendal; Lilly-Ann A van der Velden; Judi N A van Diessen; Erik van Werkhoven; Willem M C Klop; Margot E T Tesselaar Journal: Cancers (Basel) Date: 2016-02-16 Impact factor: 6.639
Authors: Arlene L Oei; Lianne E M Vriend; Caspar M van Leeuwen; Hans M Rodermond; Rosemarie Ten Cate; Anneke M Westermann; Lukas J A Stalpers; Johannes Crezee; Roland Kanaar; H Petra Kok; Przemek M Krawczyk; Nicolaas A P Franken Journal: Oncotarget Date: 2017-03-07
Authors: Muhammad Shahid Iqbal; Cheng Chaw; Josef Kovarik; Shahzeena Aslam; Aaron Jackson; John Kelly; Werner Dobrowsky; Charles Kelly Journal: Int Arch Otorhinolaryngol Date: 2016-12-19
Authors: Tejpal Gupta; Jai Prakash Agarwal; Sarbani Ghosh-Laskar; Purvish M Parikh; Anil K D'Cruz; Ketayun A Dinshaw Journal: Head Neck Oncol Date: 2009-06-15
Authors: Hendrik Andreas Wolff; Tobias Overbeck; Ralph M Roedel; Robert M Hermann; Markus K A Herrmann; Tereza Kertesz; Hilke Vorwerk; Andrea Hille; Christoph Matthias; Clemens F Hess; Hans Christiansen Journal: J Cancer Res Clin Oncol Date: 2008-12-24 Impact factor: 4.553